Deubiquitination and Stabilization of PD-L1 by CSN5

Cancer Cell

Volumn 30, Issue 6, 2016, Pages 925-939

  Lim, Seung Oe ^a   Li, Chia Wei ^a   Xia, Weiya ^a   Cha, Jong Ho ^a,c   Chan, Li Chuan ^a,b   Wu, Yun ^a   Chang, Shih Shin ^a,b   Lin, Wan Chi ^a   Hsu, Jung Mao ^a   Hsu, Yi Hsin ^a   Kim, Taewan ^a   Chang, Wei Chao ^d   Hsu, Jennifer L ^a,d   Yamaguchi, Hirohito ^a   Ding, Qingqing ^a   Wang, Yan ^a   Yang, Yi ^a   Chen, Chung Hsuan ^f   Sahin, Aysegul A ^a   Yu, Dihua ^a,b   Hortobagyi, Gabriel N ^a   Hung, Mien Chie ^a,b,d,e   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c Seoul National University   (South Korea)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e ASIA UNIVERSITY   (Taiwan)

^f GENOMICS RESEARCH CENTER   (Taiwan)

Author keywords

anti CTLA4; CSN5; curcumin; deubiquitination; PD L1; TNF

Indexed keywords

COP9 SIGNALOSOME 5; CURCUMIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DEUBIQUITINASE; GRANZYME B; POLYINOSINIC POLYCYTIDYLIC ACID; PROGRAMMED DEATH 1 LIGAND 1; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; COPS5 PROTEIN, HUMAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEPTIDE HYDROLASE; SIGNAL PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL LIKE BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CHRONIC INFLAMMATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOSURVEILLANCE; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STABILITY; TRANSCRIPTION INITIATION; UBIQUITINATION; UPREGULATION; ANIMAL; CANCER TRANSPLANTATION; CHEMISTRY; METABOLISM; NEOPLASM; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD274; CELL LINE, TUMOR; CURCUMIN; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS; NF-KAPPA B; PEPTIDE HYDROLASES; PROTEIN STABILITY; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITINATION;

EID: 85004025764     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.10.010     Document Type: Article

References (40)

1. Aggarwal, B.B., Kumar, A., Bharti, A.C., Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 23 (2003), 363–398.
2. Bech-Otschir, D., Kraft, R., Huang, X., Henklein, P., Kapelari, B., Pollmann, C., Dubiel, W., COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. EMBO J. 20 (2001), 1630–1639.
3. Blonska, M., Lin, X., NF-kappaB signaling pathways regulated by CARMA family of scaffold proteins. Cell Res. 21 (2011), 55–70.
4. Brahmer, J.R., Drake, C.G., Wollner, I., Powderly, J.D., Picus, J., Sharfman, W.H., Stankevich, E., Pons, A., Salay, T.M., McMiller, T.L., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28 (2010), 3167–3175.
5. Brown, J.A., Dorfman, D.M., Ma, F.R., Sullivan, E.L., Munoz, O., Wood, C.R., Greenfield, E.A., Freeman, G.J., Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol. 170 (2003), 1257–1266.
6. Brunet, J.F., Denizot, F., Luciani, M.F., Roux-Dosseto, M., Suzan, M., Mattei, M.G., Golstein, P., A new member of the immunoglobulin superfamily–CTLA-4. Nature 328 (1987), 267–270.
7. Callahan, M.K., Postow, M.A., Wolchok, J.D., CTLA-4 and PD-1 pathway blockade: combinations in the clinic. Front Oncol., 4, 2014, 385.
8. Colotta, F., Allavena, P., Sica, A., Garlanda, C., Mantovani, A., Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30 (2009), 1073–1081.
9. Cope, G.A., Suh, G.S., Aravind, L., Schwarz, S.E., Zipursky, S.L., Koonin, E.V., Deshaies, R.J., Role of predicted metalloprotease motif of Jab1/Csn5 in cleavage of Nedd8 from Cul1. Science 298 (2002), 608–611.
10. Coussens, L.M., Werb, Z., Inflammation and cancer. Nature 420 (2002), 860–867.
11. Dong, H., Strome, S.E., Salomao, D.R., Tamura, H., Hirano, F., Flies, D.B., Roche, P.C., Lu, J., Zhu, G., Tamada, K., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8 (2002), 793–800.
12. Echalier, A., Pan, Y., Birol, M., Tavernier, N., Pintard, L., Hoh, F., Ebel, C., Galophe, N., Claret, F.X., Dumas, C., Insights into the regulation of the human COP9 signalosome catalytic subunit, CSN5/Jab1. Proc. Natl. Acad. Sci. USA 110 (2013), 1273–1278.
13. Fang, L., Lu, W., Choi, H.H., Yeung, S.C., Tung, J.Y., Hsiao, C.D., Fuentes-Mattei, E., Menter, D., Chen, C., Wang, L., et al. ERK2-Dependent phosphorylation of CSN6 is critical in colorectal cancer development. Cancer Cell 28 (2015), 183–197.
14. Faurschou, A., Gniadecki, R., TNF-alpha stimulates Akt by a distinct aPKC-dependent pathway in premalignant keratinocytes. Exp. Dermatol. 17 (2008), 992–997.
15. Gowrishankar, K., Gunatilake, D., Gallagher, S.J., Tiffen, J., Rizos, H., Hersey, P., Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-kappaB. PLoS One, 10, 2015, e0123410.
16. Hu, M.C., Lee, D.F., Xia, W., Golfman, L.S., Ou-Yang, F., Yang, J.Y., Zou, Y., Bao, S., Hanada, N., Saso, H., et al. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117 (2004), 225–237.
17. Huang, G., Wen, Q., Zhao, Y., Gao, Q., Bai, Y., NF-kappaB plays a key role in inducing CD274 expression in human monocytes after lipopolysaccharide treatment. PLoS One, 8, 2013, e61602.
18. Ishida, Y., Agata, Y., Shibahara, K., Honjo, T., Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11 (1992), 3887–3895.
19. Krummel, M.F., Allison, J.P., CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182 (1995), 459–465.
20. Lee, D.F., Kuo, H.P., Chen, C.T., Hsu, J.M., Chou, C.K., Wei, Y., Sun, H.L., Li, L.Y., Ping, B., Huang, W.C., et al. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 130 (2007), 440–455.
21. Li, C.W., Xia, W., Huo, L., Lim, S.O., Wu, Y., Hsu, J.L., Chao, C.H., Yamaguchi, H., Yang, N.K., Ding, Q., et al. Epithelial-mesenchymal transition induced by TNF-alpha requires NF-kappaB-mediated transcriptional upregulation of Twist1. Cancer Res. 72 (2012), 1290–1300.
22. Li, C.W., Lim, S.O., Xia, W., Lee, H.H., Li, C.C., Kuo, C.W., Khoo, K.H., Chang, S.S., Cha, J.H., Kim, T., et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat. Commun., 7, 2016, 12632.
23. Liu, Y., Shah, S.V., Xiang, X., Wang, J., Deng, Z.B., Liu, C., Zhang, L., Wu, J., Edmonds, T., Jambor, C., et al. COP9-associated CSN5 regulates exosomal protein deubiquitination and sorting. Am. J. Pathol. 174 (2009), 1415–1425.
24. Lu, H., Ouyang, W., Huang, C., Inflammation, a key event in cancer development. Mol. Cancer Res. 4 (2006), 221–233.
25. Luo, J.L., Maeda, S., Hsu, L.C., Yagita, H., Karin, M., Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 6 (2004), 297–305.
26. Mombaerts, P., Iacomini, J., Johnson, R.S., Herrup, K., Tonegawa, S., Papaioannou, V.E., RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68 (1992), 869–877.
27. Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12 (2012), 252–264.
28. Peng, J., Hamanishi, J., Matsumura, N., Abiko, K., Murat, K., Baba, T., Yamaguchi, K., Horikawa, N., Hosoe, Y., Murphy, S.K., et al. Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-kappaB to foster an immunosuppressive tumor microenvironment in ovarian cancer. Cancer Res. 75 (2015), 5034–5045.
29. Postow, M.A., Callahan, M.K., Wolchok, J.D., Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33 (2015), 1974–1982.
30. Rodriguez-Garcia, M., Porichis, F., de Jong, O.G., Levi, K., Diefenbach, T.J., Lifson, J.D., Freeman, G.J., Walker, B.D., Kaufmann, D.E., Kavanagh, D.G., Expression of PD-L1 and PD-L2 on human macrophages is up-regulated by HIV-1 and differentially modulated by IL-10. J. Leukoc. Biol. 89 (2011), 507–515.
31. Sznol, M., Chen, L., Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin. Cancer Res. 19 (2013), 1021–1034.
32. Tomoda, K., Yoneda-Kato, N., Fukumoto, A., Yamanaka, S., Kato, J.Y., Multiple functions of Jab1 are required for early embryonic development and growth potential in mice. J. Biol. Chem. 279 (2004), 43013–43018.
33. Uhle, S., Medalia, O., Waldron, R., Dumdey, R., Henklein, P., Bech-Otschir, D., Huang, X., Berse, M., Sperling, J., Schade, R., Dubiel, W., Protein kinase CK2 and protein kinase D are associated with the COP9 signalosome. EMBO J. 22 (2003), 1302–1312.
34. Walunas, T.L., Lenschow, D.J., Bakker, C.Y., Linsley, P.S., Freeman, G.J., Green, J.M., Thompson, C.B., Bluestone, J.A., CTLA-4 can function as a negative regulator of T cell activation. Immunity 1 (1994), 405–413.
35. Wan, M., Cao, X., Wu, Y., Bai, S., Wu, L., Shi, X., Wang, N., Jab1 antagonizes TGF-beta signaling by inducing Smad4 degradation. EMBO Rep. 3 (2002), 171–176.
36. Wang, Y., Ding, Q., Yen, C.J., Xia, W., Izzo, J.G., Lang, J.Y., Li, C.W., Hsu, J.L., Miller, S.A., Wang, X., et al. The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell 21 (2012), 374–387.
37. Welteke, V., Eitelhuber, A., Duwel, M., Schweitzer, K., Naumann, M., Krappmann, D., COP9 signalosome controls the Carma1-Bcl10-Malt1 complex upon T-cell stimulation. EMBO Rep. 10 (2009), 642–648.
38. Wu, Y., Deng, J., Rychahou, P.G., Qiu, S., Evers, B.M., Zhou, B.P., Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell 15 (2009), 416–428.
39. Yanagawa, Y., Iijima, N., Iwabuchi, K., Onoe, K., Activation of extracellular signal-related kinase by TNF-alpha controls the maturation and function of murine dendritic cells. J. Leukoc. Biol. 71 (2002), 125–132.
40. Zou, W., Wolchok, J.D., Chen, L., PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci. Transl. Med., 8, 2016, 328rv324.